Veracyte Inc. (VCYT)
NASDAQ: VCYT
· Real-Time Price · USD
30.07
-0.15 (-0.50%)
At close: Aug 18, 2025, 3:59 PM
30.07
-0.02%
After-hours: Aug 18, 2025, 04:10 PM EDT
-0.50% (1D)
| Bid | 28.77 |
| Market Cap | 2.37B |
| Revenue (ttm) | 479.13M |
| Net Income (ttm) | 26.34M |
| EPS (ttm) | 0.34 |
| PE Ratio (ttm) | 88.46 |
| Forward PE | 22.09 |
| Analyst | Buy |
| Ask | 31 |
| Volume | 476,122 |
| Avg. Volume (20D) | 1,698,164.5 |
| Open | 30.16 |
| Previous Close | 30.22 |
| Day's Range | 29.97 - 30.59 |
| 52-Week Range | 22.61 - 47.32 |
| Beta | 1.97 |
About VCYT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol VCYT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for VCYT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Veracyte Inc. is scheduled to release its earnings on
Nov 5, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
+7.04%
Veracyte shares are trading higher amid the announ...
Unlock content with
Pro Subscription
5 months ago
+0.46%
Veracyte shares are trading lower. The company reported Q4 financial results.
1 week ago · fool.com
Veracyte (VCYT) Q2 Revenue Jumps 14%Veracyte (VCYT) Q2 Revenue Jumps 14%
1 month ago · businesswire.com
Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter of 2025...
